Tag
This article explores how the autotaxin/lysophosphatidic acid axis regulates macrophage-driven osteoclastogenesis and inflammation in periodontitis, highlighting the therapeutic potential of autotaxin inhibitors to prevent alveolar bone res
This Phase 1b trial demonstrates that oral NLRP3 inhibition with ruvonoflast markedly reduces systemic inflammatory biomarkers in obese individuals at elevated cardiovascular risk, with favorable safety and tolerability, supporting further
This study reveals sustained elevations in inflammatory and cartilage metabolism serum biomarkers during the first year after ACL reconstruction, indicating ongoing joint biological responses beyond surgery and rehabilitation.
This article evaluates the presence of micro- and nano-plastics in coronary blood of patients with ischemic heart disease, linking their burden to acute coronary events, air pollution exposure, and inflammation, highlighting a novel environ
This study reveals bidirectional mediation between BMI and inflammatory markers affecting embryo quality and availability in PCOS women undergoing ART, highlighting BMI’s predominant role.
This study reveals extensive molecular changes in amniotic fluid proteomes during the execution phase of human labor, highlighting distinct biological processes linked to cervical dilatation stages at term.
Early postoperative peripheral parenteral nutrition after colorectal resection reduces inflammatory markers and improves nitrogen balance without increasing complications, suggesting a beneficial supportive strategy in surgical recovery man
An epigenome-wide study reveals that DNA methylation markers linked to inflammatory pathways and blood lipid traits play a causal role in abdominal aortic aneurysm development, offering potential for improved risk prediction and therapeutic
Germline and somatic variants in DNMT3A and other CHIP genes elevate pulmonary arterial hypertension risk, including connective tissue disease-associated forms, through pro-inflammatory pathways, highlighting novel biomarkers and therapeuti
TP53-mutant clonal hematopoiesis in CAR T-cell recipients is linked to a pro-inflammatory state, cytopenias, and worse survival, highlighting the importance of tailored monitoring strategies in this high-risk group.
In the SELECT trial, semaglutide significantly lowered hsCRP levels and major cardiovascular events in patients with established atherosclerotic cardiovascular disease and overweight or obesity, suggesting inflammation reduction as a possib
This study reveals how HIF2 activation drives coronary artery remodeling, inflammation, and thrombosis in a mouse model mirroring severe Kawasaki disease, uncovering new therapeutic targets for coronary complications.
This article examines interleukin-6 (IL-6) as a key mediator of therapeutic efficacy in acute lung injury and COVID-19, highlighting its role in modulating inflammation and survival outcomes across multiple clinical interventions.
This review explores the role of dysregulated iron metabolism and inflammation, particularly elevated serum ferritin, in isolated REM sleep behavior disorder (iRBD) as a prodromal stage of neurodegeneration, synthesizing recent longitudinal
Severe burns alter extracellular vesicle protein cargo, revealing coordinated immune and neuronal signaling changes that drive inflammation and healing responses, suggesting novel biomarker and therapeutic avenues.
GLP-1 receptor agonists significantly reduce atherosclerosis progression, inflammatory biomarkers, and cardiovascular events independent of glycaemic control and obesity status, evidenced by robust preclinical and large-scale clinical data.
Elevated lipoprotein(a) increases coronary artery disease risk, but this study reveals that inflammation—particularly IL-6 levels—modulates this risk, highlighting the importance of inflammatory biomarkers in cardiovascular risk assessment
Higher blood IL-6 levels were strongly linked to nine cardiovascular and mortality outcomes in nearly 60,000 adults, supporting IL-6 as an important inflammatory marker and potential prevention target.
A small randomized trial found that blocking IL-6 with tocilizumab showed promising, clinically meaningful trends for inflammation-related, hard-to-treat depression, especially for somatic symptoms, fatigue, anxiety, and quality of life, th
A pooled analysis of 59,396 participants found that higher serum IL-6 concentrations independently predicted nine cardiovascular and mortality outcomes, with consistent associations across key clinical subgroups.
